October 18, 2017
A Massachusetts federal judge renewed his criticism Wednesday for plea bargains that deprive courts of sentencing discretion, but stopped short of tossing out a $36 million deal that would preclude him from weighing in on the ramifications of Aegerion Pharmaceuticals Inc. admitting to fraud in connection with its expensive cholesterol drug.
September 22, 2017
Massachusetts-based biopharmaceutical company Aegerion Pharmaceuticals Inc. agreed Friday to pay about $40 million to end criminal and civil allegations by the U.S. Department of Justice and fraud charges brought by the U.S. Securities and Exchange Commission over an expensive cholesterol treatment.